Literature DB >> 28844846

Analysis of polymorphic contamination in meloxicam raw materials and its effects on the physicochemical quality of drug product.

Jennifer T Jacon Freitas1, Olimpia M M Santos Viana2, Rudy Bonfilio3, Antônio Carlos Doriguetto4, Magali Benjamim de Araújo5.   

Abstract

This work aims to evaluate the effect of polymorphism on the physicochemical properties of meloxicam, which is an antipyretic and non-steroidal anti-inflammatory drug. Powder X-ray Diffraction, Infrared Spectroscopy with attenuated total reflectance, Thermogravimetric and Differential Scanning Calorimetry techniques were used for the polymorphic characterization. Comparative tests of solubility, intrinsic dissolution and dissolution profiles were performed on meloxicam active pharmaceutical ingredients (APIs) and formulated tablets. A polymorphic contamination (Forms I and III) was found in a studied meloxicam batch, which showed a higher solubility and greater intrinsic dissolution than those containing only the preconized form (Form I). Consequently, the dissolution profiles of the tablets that contained the polymorphic contamination showed higher drug release. Additionally, a thermal behavior study shows that MLX Form I and III are monotropy polymorphs being MLX Form III a metastable phase, which becomes MLX Form I at approximately 200°C in solid state phase transition governed by kinetic variables. The kinetic of conversion of Form III to Form I in saturated solutions was also studied. These results illustrate the importance of the polymorphic characterization of meloxicam APIs and formulated tablets in order to avoid potential quality and efficacy problems of drug products.
Copyright © 2017 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Dissolution profile; Intrinsic dissolution; Meloxicam; Meloxicam (PubChem CID: 54677470); Polymorphism; Powder X-ray diffraction; Solubility

Mesh:

Substances:

Year:  2017        PMID: 28844846     DOI: 10.1016/j.ejps.2017.08.029

Source DB:  PubMed          Journal:  Eur J Pharm Sci        ISSN: 0928-0987            Impact factor:   4.384


  6 in total

1.  Mouse Behavior in the Open-field Test after Meloxicam Administration.

Authors:  Ana Tfb Antiorio; Jilma Alemán-Laporte; Dennis A Zanatto; Marco A A Pereira; Mariana Sag Gomes; Danilo Wadt; Pedro K Yamamoto; Maria M Bernardi; Claudia Mc Mori
Journal:  J Am Assoc Lab Anim Sci       Date:  2022-01-31       Impact factor: 1.706

2.  Intermolecular interaction as a direct measure of water solubility advantage of meloxicam cocrystalized with carboxylic acids.

Authors:  Piotr Cysewski
Journal:  J Mol Model       Date:  2018-04-21       Impact factor: 1.810

3.  Smartcrystals for Efficient Dissolution of Poorly Water-Soluble Meloxicam.

Authors:  Rita Ambrus; Areen Alshweiat; Piroska Szabó-Révész; Csilla Bartos; Ildikó Csóka
Journal:  Pharmaceutics       Date:  2022-01-21       Impact factor: 6.321

4.  Multiparticulate Systems of Meloxicam for Colonic Administration in Cancer or Autoimmune Diseases.

Authors:  Eva Navarro-Ruíz; Covadonga Álvarez-Álvarez; M Ángeles Peña; Carlos Torrado-Salmerón; Zaid Dahma; Paloma Marina de la Torre-Iglesias
Journal:  Pharmaceutics       Date:  2022-07-20       Impact factor: 6.525

5.  Solid Form and Phase Transformation Properties of Fexofenadine Hydrochloride during Wet Granulation Process.

Authors:  Suye Li; Hengqian Wu; Yanna Zhao; Ruiyan Zhang; Zhengping Wang; Jun Han
Journal:  Pharmaceutics       Date:  2021-05-27       Impact factor: 6.321

6.  The Evaluation of Meloxicam Nanocrystals by Oral Administration with Different Particle Sizes.

Authors:  Yao Yu; Yang Tian; Hui Zhang; Qingxian Jia; Xuejun Chen; Dongzhou Kang; Yimeng Du; Shenghan Song; Aiping Zheng
Journal:  Molecules       Date:  2022-01-10       Impact factor: 4.411

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.